Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 52 in last 24h · 115,243 total before filter · latest 1h ago
52last 24h
1809last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
AllMacro322Earnings856M&A105Regulatory25Product16Analyst25
✕ clear all filtersticker: PLTRsentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Prediction: 1 AI Stock That Could Be a Monster Winner
24/7 Wall St.1d agoneutral
Prediction: 1 AI Stock That Could Be a Monster Winner

Palantir just delivered the most explosive quarter in its history, yet its stock sits nearly flat for the year. Something has to give, and the gap between where shares trade today and where the numbers say they could go tells a striking story.

Palantir Technologies (PLTR) Is Up 8.0% After Raising 2026 Revenue Guidance On Stronger Q2 Results
Simply Wall St.2d agoneutral
Palantir Technologies (PLTR) Is Up 8.0% After Raising 2026 Revenue Guidance On Stronger Q2 Results

In early August 2026, Palantir Technologies reported second-quarter results showing sales of US$1.94 billion and net income of US$1.06 billion, alongside stronger performance for the first half of the year and higher earnings per share than a year earlier. Management also raised full-year 2026 revenue guidance to between US$8.15–US$8.16 billion and reiterated expectations for GAAP profitability each quarter, underscoring confidence that demand for its AI platforms will support continued...

Inovio Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat2d agoneutral
Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara

Zeta Global’s Q2 Earnings Call: Our Top 5 Analyst Questions
StockStory2d agoneutral
Zeta Global’s Q2 Earnings Call: Our Top 5 Analyst Questions

Zeta Global's second quarter saw robust top-line growth, surpassing Wall Street’s revenue and profit expectations. Despite this, the market reacted negatively following the results. Management attributed the strong quarter to accelerated adoption of Zeta’s AI-powered Athena platform and deeper cross-industry partnerships, particularly with OpenAI, Palantir, and Snowflake. CEO David Steinberg emphasized that “Athena is fundamentally changing how customers interact with the Zeta platform,” highlig

Michael Burry delivers brutal verdict on $420 billion AI giant
TheStreet3d agoneutral
Michael Burry delivers brutal verdict on $420 billion AI giant

I covered Michael Burry's first Palantir short thesis on June 4, when he called the stock a "sand castle" trading at 16 times intrinsic value. The stock dropped sharply the following day. Then Palantir reported one of the most extraordinary quarters in enterprise software history. On top of ...

Palantir and These Software Stocks Slide in Seesaw With Chip Giants
Barrons.com3d agoneutral
Palantir and These Software Stocks Slide in Seesaw With Chip Giants

Palantir slid 1.3% and Microsoft dipped 0.7% in the premarket. Salesforce ServiceNow and Workday were among the other software stocks trading in the red. The moves came as shares of chip and optical networking companies rallied, following a strong batch of earnings reports that signaled to the market that demand for AI remains robust.